|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Acorda Therapeutics (ACOR) Reports First Quarter 2012 Financial Results
5/3/2012 10:14:08 AM
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the first quarter ended March 31, 2012. “AMPYRA continues to make unique and important contributions to the lives of people with MS. We were pleased to see consumer demand for AMPYRA increase progressively beginning in February, in response to our outreach programs,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “We are excited about the potential for AMPYRA also to help patients with other neurological conditions, such as post-stroke deficits and cerebral palsy. We have accelerated the start of our proof-of-concept post-stroke deficit study, which we now expect to begin in the second quarter of 2012, and we expect initial results from our cerebral palsy study by the end of the year.”
|
|
|
|
|
|
|
|
|
|
|